

Supporting Information

Monoclonal Antibody Against the Turn of the 42-Residue Amyloid β -Protein at Positions 22 and 23

Kazuma Murakami^{1,2,†}, Yuko Horikoshi-Sakuraba⁴, Nakaba Murata^{2,5}, Yoshihiro Noda², Yuichi Masuda^{1,†}, Noriaki Kinoshita⁴, Hiroyuki Hatsuta³, Shigeo Murayama³, Takuji Shirasawa⁶, Takahiko Shimizu^{2,5,**}, and Kazuhiro Irie^{1*}

¹Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Kyoto 606-8502, Japan

²Molecular Gerontology, or ³Department of Neuropathology, Tokyo Metropolitan Institute of Gerontology, Itabashi-ku, Tokyo 173-0015, Japan

⁴Immuno-Biological Laboratories Co, Ltd., Gunma 370-0831, Japan

⁵Applied Biological Chemistry, United Graduate School of Agricultural Science, Tokyo University of Agriculture and Technology, Fuchu-shi, Tokyo 183-8509, Japan

⁶Department of Aging Control Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo 113-0033, Japan

[†]Research Fellow of the Japan Society for the Promotion of Science

*, **Correspondence authors

[Contents]

Figure S1. MALDI-TOF-MS data for (A) G9C, E22P-A β 9–35 and (B) E22P-A β 9–35.




Figure S1. MALDI-TOF-MS data for (A) G9C, E22P-A β 9-35 and (B) E22P-A β 9-35.